Edition:
India

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

32.21USD
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
$32.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
305,528
52-wk High
$86.22
52-wk Low
$31.21

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $4,124.93
Shares Outstanding(Mil.): 48.88
Dividend: --
Yield (%): --

Financials

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON, Sept 18 U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS

09 May 2018

BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million

* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:

28 Apr 2018

BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK

17 Apr 2018

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $200 Mln Principal Amount Of Convertible Senior Notes

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $200 MILLION PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025 - SEC FILING Source text: (https://bit.ly/2qzin28) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2HCYkbd) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers

* CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING

10 Apr 2018

BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer

* RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER

06 Apr 2018

EMA panel for conditional OK to Clovis's ovarian cancer drug

A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.

23 Mar 2018

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥10,600 +55.00
Pfizer Inc. (PFE.N) $43.86 +0.60
AstraZeneca plc (AZN.L) 5,572.00 -29.00
BioMarin Pharmaceutical Inc. (BMRN.OQ) $101.08 +1.31
TESARO Inc (TSRO.OQ) $37.84 +0.83
AbbVie Inc (ABBV.N) $92.82 +1.80
Novartis AG (NOVN.S) CHF81.94 +0.20
Johnson & Johnson (JNJ.N) $142.04 +1.58
Eli Lilly And Co (LLY.N) $105.92 +0.18
GlaxoSmithKline plc (GSK.L) 1,485.80 -11.00

Earnings vs. Estimates